Current Report Filing (8-k)
June 21 2022 - 08:19AM
Edgar (US Regulatory)
0001558569
false
0001558569
2022-06-20
2022-06-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 20, 2022
iSpecimen Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40501 |
|
27-0480143 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
450
Bedford Street
Lexington,
MA 02420 |
(Address of principal executive offices, including zip
code) |
Registrant’s telephone
number, including area code: (781) 301-6700
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ISPC |
|
The Nasdaq
Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 | Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
Amendment to Executive Employment Agreements
On June 20, 2022, iSpecimen Inc. (the
“Company”) entered into amendments (collectively, the “Amendments”) to the executive employment agreements
of each of Christopher Ianelli, the Company’s Chief Executive Officer and President, Jill Mullan, the Company’s Chief
Operating Officer and Secretary, Tracy Curley, the Company’s Chief Financial Officer and Treasurer, and Benjamin Bielak, the
Company’s Chief Information Officer (collectively, the “Employment Agreements”). Under their initial terms, each
of the Employment Agreements would have expired on June 21, 2022. Pursuant to the Amendments, the Company and each of
Mr. Ianelli, Ms. Mullan, Ms. Curley and Mr. Bielak agreed to extend the expiration date of each of their
Employment Agreements to the earlier of (i) July 29, 2022, (ii) the death or disability of such executive, or (iii)
the occurrence of any of the termination events as described in Section 5 of their respective Employment Agreements, so that
there is sufficient time for the Company’s board of directors and each of them to complete the performance review described in
Section 3 of their respective Employment Agreements for the purpose of determining each of their compensation and performance
goals for the annual period through June 21, 2023.
Copies of the Amendments between the Company and
each of Mr. Ianelli, Ms. Mullan, Ms. Curley and Mr. Bielak are attached to this Current Report on Form 8-K as
Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, and are incorporated by reference herein.
Item 9.01 | Financial
Statements and Exhibits |
(d) Exhibits.
Exhibit No. |
|
Description |
10.1 |
|
|
First
Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Christopher Ianelli |
10.2 |
|
|
First
Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Jill Mullan |
10.3 |
|
|
First
Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Tracy Curley |
10.4 |
|
|
First
Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Benjamin Bielak |
104 |
|
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 21, 2022
|
iSPECIMEN INC. |
|
|
|
|
By: |
/s/ Christopher
Ianelli |
|
|
Name: Christopher Ianelli |
|
|
Title: Chief Executive Officer and President |
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Feb 2024 to Mar 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2023 to Mar 2024